Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ADPT

Adaptive Biotechnologies Corp

Apr 14 • 01:10PM ET

14.61

+0.48 3.43 %

Healthcare • Biotechnology • USA • NASD

Peers: ILMN TXG GH PACB QGEN TWST FATE BEAM CRSP VRTX

| Held by: VTI IWM ARKG VB VXF IWO VBK IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	3.62%	Shs Outstand	153.78M	Perf Week	6.60%
Market Cap	2.25B	Forward P/E	-	EPS next Y	-0.26	Insider Trans	-43.30%	Shs Float	148.41M	Perf Month	10.97%
Enterprise Value	2.24B	PEG	-	EPS next Q	-0.16	Inst Own	96.16%	Short Float	5.77%	Perf Quarter	-19.96%
Income	-59.50M	P/S	8.12	EPS this Y	-24.18%	Inst Trans	4.72%	Short Ratio	4.23	Perf Half Y	-3.66%
Sales	276.98M	P/B	10.27	EPS next Y	45.40%	ROA	-7.92%	Short Interest	8.56M	Perf YTD	-10.01%
Book/sh	1.42	P/C	9.91	EPS next 5Y	47.95%	ROE	-28.23%	52W High	20.76 -29.60%	Perf Year	86.89%
Cash/sh	1.47	P/FCF	-	EPS past 3/5Y	34.64% 18.85%	ROIC	-14.32%	52W Low	6.77 115.73%	Perf 3Y	84.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.34% 23.00%	Gross Margin	70.03%	Volatility	8.93% 6.33%	Perf 5Y	-65.68%
Dividend TTM	-	EV/Sales	8.09	EPS Y/Y TTM	63.63%	Oper. Margin	-20.62%	ATR (14)	1.01	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.23	Sales Y/Y TTM	54.77%	Profit Margin	-21.48%	RSI (14)	52.59	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.34	EPS Q/Q	61.13%	SMA20	6.15%	Beta	2.29	Target Price	20.57
Payout	-	Debt/Eq	0.96	Sales Q/Q	51.04%	SMA50	-1.99%	Rel Volume	0.39	Prev Close	14.13
Employees	624	LT Debt/Eq	0.90	Earnings	Feb 05 AMC	SMA200	-0.80%	Avg Volume	2.02M	Price	14.61
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	51.48% 17.72%	Trades		Volume	463,594	Change	3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$21
Sep-30-25	Initiated	Guggenheim	Buy	$20
Jun-18-25	Initiated	Craig Hallum	Buy	$15
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$9
Jul-05-23	Resumed	JP Morgan	Overweight	$15
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$15
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight	$7.50 → $14
Aug-25-22	Initiated	Credit Suisse	Underperform	$8
Jun-03-22	Initiated	Piper Sandler	Neutral	$7.50
Feb-16-22	Reiterated	JP Morgan	Overweight	$75 → $50
Feb-16-22	Reiterated	Goldman	Neutral	$54 → $21
Feb-16-22	Reiterated	BTIG Research	Buy	$35 → $30
Feb-16-22	Reiterated	BofA Securities	Buy	$40 → $32
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral	$74 → $63
Oct-08-20	Resumed	BTIG Research	Buy	$60
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight	$42
Jun-03-20	Initiated	Goldman	Buy	$60
Jul-23-19	Initiated	BTIG Research	Buy	$46
Jul-22-19	Initiated	William Blair	Outperform

Show Previous Ratings

Mar-02-26 08:10PM	Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf. (MarketBeat)
Feb-28-26 02:14AM	Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? (Insider Monkey)
Feb-21-26 06:01AM	TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT) (Insider Monkey)
Feb-06-26 08:30AM	Adaptive Biotechnologies Corporation Q4 2025 Earnings Call Summary (Moby)
12:05AM	Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
08:06PM	Loading…
Feb-05-26 08:06PM	Adaptive Biotechnologies Q4 Earnings Call Highlights (MarketBeat)
07:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-27-26 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-26 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (GlobeNewswire) +8.48%
Jan-13-26 09:40AM	What's Going On With Adaptive Biotechnologies Shares Tuesday? (Benzinga)
Jan-12-26 09:06PM	Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 (MarketBeat) +15.86%
07:30AM	Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
04:05PM	Loading…
Dec-30-25 04:05PM	Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 08:00AM	Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer (GlobeNewswire)
Dec-09-25 05:07PM	Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease (GlobeNewswire) +5.92%
Dec-08-25 02:16AM	Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake (Insider Monkey)
Dec-06-25 08:30AM	Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-24-25 07:30AM	Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting (GlobeNewswire) +9.94%
Nov-22-25 10:10AM	Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why (Insider Monkey)
Nov-17-25 09:05AM	Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 (Insider Monkey)
Nov-06-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.54%
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
12:03AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Nov-05-25 07:30PM	Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:31PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	Loading…
Nov-04-25 07:45AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-17-25 12:10PM	Can This Red-Hot Biotech Stock Live Up to Wall Streets Expectations? (Barchart) -5.62%
Oct-15-25 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.82%
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Sep-23-25 12:08PM	CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU (Zacks)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks) +8.62%
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
09:40AM	Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice (Zacks)
Aug-29-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-27-25 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
12:08AM	Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination (Insider Monkey)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-08-25 09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-06-25 07:01PM	Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday (Motley Fool) +5.79% +7.27%
03:30AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... (GuruFocus.com)
Aug-05-25 07:30PM	Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings (Zacks)
06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:38AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.61%
Aug-01-25 08:10AM	Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-22-25 08:14AM	Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results (Insider Monkey)
Jul-15-25 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Jul-01-25 07:30AM	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR (GlobeNewswire)
Jun-26-25 09:49AM	Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Jun-25-25 01:01PM	Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy (Insider Monkey) +12.49%
Jun-13-25 12:00PM	What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock (Zacks)
Jun-11-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-25 04:05PM	Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors (Business Wire)
May-30-25 07:30AM	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers (GlobeNewswire)
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
06:20AM	Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? (Zacks)
May-28-25 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-26-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
May-20-25 06:20AM	Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
May-15-25 08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
May-09-25 12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:00PM	Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 09:55AM	Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect? (Zacks) +5.22%
09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
May-02-25 09:29AM	Q1 2025 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents) +33.70%
03:18AM	Adaptive Biotechnologies Corp (ADPT) Q1 2025 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)
May-01-25 09:46PM	Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:00PM	Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-24-25 09:45AM	Aristotle Focus Growth Q1 2025 Commentary (Seeking Alpha) +6.91%
Apr-14-25 02:09PM	Aristotle Large Cap Growth Q1 2025 Commentary (Seeking Alpha)
Apr-12-25 09:15AM	OpenAI And Andreessen Horowitz Lead $43M Round For Cybersecurity Startup Taking On AI Scammers, Deepfakes, And Voice Spoofs (Benzinga)
Apr-10-25 04:05PM	Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire) -7.82%

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBINSTEIN JULIE	President and COO	Apr 13 '26	Option Exercise	7.80	14,722	114,898	440,234	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 09 '26	Option Exercise	7.27	14,722	107,029	448,910	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 10 '26	Option Exercise	7.27	14,722	107,029	444,572	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 09 '26	Sale	13.86	19,060	264,202	429,850	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 13 '26	Sale	13.15	19,060	250,599	421,174	Apr 13 07:44 PM
RUBINSTEIN JULIE	President and COO	Apr 10 '26	Sale	12.77	19,060	243,307	425,512	Apr 13 07:44 PM
LO FRANCIS	Chief People Officer	Apr 08 '26	Option Exercise	3.99	2,344	9,353	293,718	Apr 10 06:52 PM
LO FRANCIS	Chief People Officer	Apr 08 '26	Sale	15.07	22,564	340,039	271,154	Apr 10 06:52 PM
ROBINS HARLAN S	Chief Scientific Officer	Apr 08 '26	Sale	14.85	10,000	148,500	1,512,058	Apr 10 06:48 PM
ROBINS CHAD M	CEO and Chairman	Apr 06 '26	Sale	14.41	83,332	1,200,814	2,217,781	Apr 08 07:51 PM
ROBINS CHAD M	CEO and Chairman	Apr 08 '26	Sale	15.19	37,263	566,025	2,180,518	Apr 08 07:51 PM
RUBINSTEIN JULIE	President and COO	Apr 08 '26	Option Exercise	9.44	26,603	251,264	465,129	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 06 '26	Option Exercise	7.27	14,722	107,029	461,924	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 07 '26	Option Exercise	7.27	14,722	107,029	457,586	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 08 '26	Sale	14.83	30,941	458,920	434,188	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 06 '26	Sale	14.33	19,060	273,130	442,864	Apr 08 07:48 PM
RUBINSTEIN JULIE	President and COO	Apr 07 '26	Sale	13.56	19,060	258,454	438,526	Apr 08 07:48 PM
Harlan Robins	Officer	Apr 08 '26	Proposed Sale	14.84	10,000	148,400		Apr 08 04:58 PM
Chad Robins	Officer	Apr 08 '26	Proposed Sale	14.84	37,263	552,983		Apr 08 04:58 PM
FRANCIS LO	Officer	Apr 08 '26	Proposed Sale	13.71	22,564	309,352		Apr 08 04:33 PM
Chad Robins	Officer	Apr 06 '26	Proposed Sale	14.08	83,332	1,173,315		Apr 06 05:22 PM
RUBINSTEIN JULIE	President and COO	Apr 01 '26	Option Exercise	7.27	14,722	107,029	470,600	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 02 '26	Option Exercise	7.27	14,722	107,029	466,262	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 02 '26	Sale	14.60	19,060	278,276	447,202	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Apr 01 '26	Sale	14.45	19,060	275,417	451,540	Apr 02 07:16 PM
RUBINSTEIN JULIE	President and COO	Mar 27 '26	Option Exercise	7.27	14,722	107,029	483,614	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 30 '26	Option Exercise	7.27	14,722	107,029	479,276	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 31 '26	Option Exercise	7.27	14,722	107,029	474,938	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 31 '26	Sale	13.45	19,060	256,357	455,878	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 27 '26	Sale	13.34	19,060	254,218	464,554	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 30 '26	Sale	12.63	19,060	240,728	460,216	Mar 31 06:56 PM
RUBINSTEIN JULIE	President and COO	Mar 24 '26	Option Exercise	7.27	14,722	107,029	496,628	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 25 '26	Option Exercise	7.27	14,722	107,029	492,290	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 26 '26	Option Exercise	7.27	14,722	107,029	487,952	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 25 '26	Sale	14.27	19,060	271,986	473,230	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 26 '26	Sale	14.12	19,060	269,127	468,892	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 24 '26	Sale	13.70	19,060	261,122	477,568	Mar 26 07:41 PM
RUBINSTEIN JULIE	President and COO	Mar 23 '26	Option Exercise	7.27	14,722	107,029	500,966	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 20 '26	Option Exercise	7.08	14,722	104,193	505,304	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 19 '26	Option Exercise	6.55	14,722	96,429	509,642	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 23 '26	Sale	13.83	19,060	263,600	481,906	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 20 '26	Sale	13.37	19,060	254,832	486,244	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 19 '26	Sale	13.18	19,060	251,211	490,582	Mar 23 07:18 PM
RUBINSTEIN JULIE	President and COO	Mar 16 '26	Option Exercise	6.55	14,722	96,429	522,656	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 17 '26	Option Exercise	6.55	14,722	96,429	518,318	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 18 '26	Option Exercise	6.55	14,722	96,429	513,980	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 16 '26	Sale	13.41	19,060	255,595	503,596	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 17 '26	Sale	13.40	19,060	255,404	499,258	Mar 18 06:21 PM
RUBINSTEIN JULIE	President and COO	Mar 18 '26	Sale	13.18	19,060	251,211	494,920	Mar 18 06:21 PM
BOBULSKY SUSAN	Officer	Mar 11 '26	Proposed Sale	14.52	41,338	600,228		Mar 16 09:05 PM
BENZENO SHARON	Officer	Mar 11 '26	Proposed Sale	14.52	63,103	916,256		Mar 16 09:00 PM
PISKEL KYLE	Officer	Mar 11 '26	Proposed Sale	14.52	18,672	271,117		Mar 16 08:53 PM
RUBINSTEIN JULIE	Officer	Mar 11 '26	Proposed Sale	14.52	122,523	1,779,034		Mar 16 08:46 PM
ROBINS HARLAN S	Officer	Mar 11 '26	Proposed Sale	14.52	470,266	6,828,262		Mar 16 08:40 PM
ROBINS CHAD M	Officer	Mar 11 '26	Proposed Sale	14.52	470,167	6,826,825		Mar 16 08:33 PM
RUBINSTEIN JULIE	President and COO	Mar 11 '26	Option Exercise	6.55	14,722	96,429	535,670	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 12 '26	Option Exercise	6.55	14,722	96,429	531,332	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 13 '26	Option Exercise	6.55	14,722	96,429	526,994	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 11 '26	Sale	13.29	141,583	1,881,993	516,610	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 13 '26	Sale	12.96	19,060	247,018	507,934	Mar 13 09:36 PM
RUBINSTEIN JULIE	President and COO	Mar 12 '26	Sale	12.86	19,060	245,048	512,272	Mar 13 09:36 PM
GRIFFIN MICHELLE RENEE	Director	Mar 11 '26	Sale	13.91	15,394	214,131	15,625	Mar 13 09:05 PM
LO FRANCIS	Chief People Officer	Mar 11 '26	Sale	14.08	30,593	430,749	291,374	Mar 13 09:02 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Mar 11 '26	Sale	13.17	41,338	544,421	427,775	Mar 13 08:59 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Mar 11 '26	Sale	13.17	63,103	831,067	272,751	Mar 13 08:55 PM
PISKEL KYLE	Chief Financial Officer	Mar 11 '26	Sale	13.17	18,672	245,910	259,840	Mar 13 08:52 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 11 '26	Sale	13.17	470,266	6,193,403	1,522,058	Mar 13 08:49 PM
ROBINS CHAD M	CEO and Chairman	Mar 11 '26	Sale	13.17	470,167	6,192,099	2,301,113	Mar 13 08:45 PM
FRANCIS LO	Officer	Mar 11 '26	Proposed Sale	14.52	30,593	444,210		Mar 11 04:42 PM
MICHELLE GRIFFIN	Director	Mar 11 '26	Proposed Sale	13.91	15,394	214,097		Mar 11 04:21 PM
RUBINSTEIN JULIE	President and COO	Mar 06 '26	Option Exercise	9.05	26,603	240,664	683,088	Mar 10 08:04 PM
RUBINSTEIN JULIE	President and COO	Mar 09 '26	Option Exercise	9.05	26,603	240,664	678,750	Mar 10 08:04 PM
RUBINSTEIN JULIE	President and COO	Mar 10 '26	Option Exercise	6.70	15,122	101,285	662,931	Mar 10 08:04 PM
RUBINSTEIN JULIE	President and COO	Mar 06 '26	Sale	15.14	30,941	468,447	652,147	Mar 10 08:04 PM
RUBINSTEIN JULIE	President and COO	Mar 09 '26	Sale	14.79	30,941	457,617	647,809	Mar 10 08:04 PM
RUBINSTEIN JULIE	President and COO	Mar 10 '26	Sale	14.68	19,460	285,673	643,471	Mar 10 08:04 PM
LO FRANCIS	Officer	Mar 05 '26	Proposed Sale	16.44	38,074	625,937		Mar 10 07:53 PM
LO FRANCIS	Chief People Officer	Mar 05 '26	Sale	15.09	38,074	574,537	321,967	Mar 09 08:29 PM
GRIFFIN MICHELLE RENEE	Director	Mar 03 '26	Option Exercise	3.99	48,044	191,696	63,438	Mar 05 08:05 PM
GRIFFIN MICHELLE RENEE	Director	Mar 03 '26	Sale	15.30	48,044	735,073	15,394	Mar 05 08:05 PM
RUBINSTEIN JULIE	President and COO	Mar 03 '26	Option Exercise	9.05	26,603	240,664	614,852	Mar 05 07:42 PM
RUBINSTEIN JULIE	President and COO	Mar 04 '26	Option Exercise	9.05	26,603	240,664	610,514	Mar 05 07:42 PM
RUBINSTEIN JULIE	President and COO	Mar 05 '26	Option Exercise	9.05	26,603	240,664	606,176	Mar 05 07:42 PM
RUBINSTEIN JULIE	President and COO	Mar 04 '26	Sale	16.60	30,941	513,621	579,573	Mar 05 07:42 PM
RUBINSTEIN JULIE	President and COO	Mar 05 '26	Sale	16.00	30,941	495,056	575,235	Mar 05 07:42 PM
RUBINSTEIN JULIE	President and COO	Mar 03 '26	Sale	15.67	30,941	484,751	583,911	Mar 05 07:42 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 03 '26	Sale	16.52	14,233	235,129	1,155,291	Mar 04 07:58 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 02 '26	Sale	15.72	10,000	157,200	1,169,524	Mar 04 07:58 PM
ROBINS CHAD M	CEO and Chairman	Mar 02 '26	Sale	15.82	289,024	4,572,360	1,987,330	Mar 03 07:51 PM
ROBINS CHAD M	CEO and Chairman	Feb 27 '26	Sale	15.99	182,891	2,924,427	2,276,354	Mar 03 07:51 PM
ROBINS CHAD M	CEO and Chairman	Mar 03 '26	Sale	15.52	53,083	823,826	1,934,247	Mar 03 07:51 PM
Harlan Robins	Officer	Mar 03 '26	Proposed Sale	16.08	14,233	228,867		Mar 03 04:59 PM
Chad Robins	Officer	Mar 03 '26	Proposed Sale	16.08	53,083	853,575		Mar 03 04:59 PM
JULIE RUBINSTEIN	Officer	Mar 03 '26	Proposed Sale	16.12	1,206,661	19,451,375		Mar 03 04:50 PM
MICHELLE GRIFFIN	Director	Mar 03 '26	Proposed Sale	16.12	48,044	774,469		Mar 03 04:50 PM
Harlan Robins	Officer	Mar 02 '26	Proposed Sale	16.12	10,000	161,200		Mar 02 05:24 PM
Chad Robins	Officer	Mar 02 '26	Proposed Sale	16.12	289,024	4,659,067		Mar 02 05:24 PM
Chad Robins	Officer	Feb 27 '26	Proposed Sale	16.02	182,891	2,929,914		Feb 27 04:47 PM
PISKEL KYLE	Chief Financial Officer	Feb 04 '26	Option Exercise	12.14	2,145	26,040	218,782	Feb 06 07:30 PM
PISKEL KYLE	Chief Financial Officer	Feb 04 '26	Sale	18.46	2,145	39,597	216,637	Feb 06 07:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADPT

Adaptive Biotechnologies Corp

Upgrade your Finviz experience